BiotechTube

Brenipatide + Placebo + Buprenorphine

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid Use Disorder

Conditions

Opioid Use Disorder

Trial Timeline

Feb 13, 2026 → Feb 1, 2028

NCT ID
NCT07420283

About Brenipatide + Placebo + Buprenorphine

Brenipatide + Placebo + Buprenorphine is a phase 2 stage product being developed by Eli Lilly for Opioid Use Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07420283. Target conditions include Opioid Use Disorder.

What happened to similar drugs?

8 of 20 similar drugs in Opioid Use Disorder were approved

Approved (8) Terminated (6) Active (7)
✅Naldemedine + PlaceboShionogiApproved
✅Polyethylene Glycol 3350 + MovantikAstraZenecaApproved
✅Naltrexone for extended-release injectable suspension + Oral naltrexoneAlkermesApproved
✅NaltrexoneAlkermesApproved
✅VIVITROL 380mgAlkermesApproved
✅methylnaltrexone + placeboBausch HealthApproved
✅Methylnaltrexone bromideBausch HealthApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07420283Phase 2Recruiting

Competing Products

20 competing products in Opioid Use Disorder

See all competitors
ProductCompanyStageHype Score
SUBLOCADEIndivior PLCPhase 3
29
SUBLOCADEIndivior PLCPhase 3
29
ASP8082 + morphine + PlaceboAstellas PharmaPhase 1
29
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 1
29
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 2
27
Naldemedine + PlaceboShionogiPhase 3
40
Naldemedine + PlaceboShionogiApproved
50
NaldemedineShionogiPhase 1/2
39
Naldemedine + PlaceboShionogiPhase 3
40
Placebo + NaldemedineShionogiPhase 2
35
Naldemedine + PlaceboShionogiPhase 3
40
Naldemedine + PlaceboShionogiPhase 2
35
NaloxegolKyowa KirinPre-clinical
26
naloxegol + non-PAMORA laxativeKyowa KirinPre-clinical
18
NaloxegolKyowa KirinPre-clinical
26
NaloxegolKyowa KirinPre-clinical
26
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
32
Naloxegol + NaloxegolAstraZenecaPhase 1
29
NKTR-118 + Usual careAstraZenecaPhase 3
40
Polyethylene Glycol 3350 + MovantikAstraZenecaApproved
43